XLO Utang jangka cendhak perusahaan Xilio Therapeutics Inc

Xilio Therapeutics, Inc. (XLO) dynamics are driven by a dependence on Gilead payments and R&D expenditures. The history of short-term liabilities demonstrates the current state of debt, where 0.00 shows the current volume of this metric. The business model relies on third-party antibody synthesis contractors. Meanwhile, high competition in tumor therapy and potential drug side effects during trials create significant challenges.

This metric aggregates all of the issuer's financial obligations with a maturity of less than twelve months, measuring the current liquidity burden. Given the loss-making R&D and the dependence of Xilio Therapeutics, Inc. (XLO) on payments from Gilead, an increase in total short-term liabilities signals a critical risk of a cash crunch in the event of delayed partner payments or negative clinical trial results.